Myeloma combo trial halted early after enrolling only 4 patients

NCT ID NCT06163898

Terminated Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen May 06, 2026 · Last updated May 06, 2026

Summary

This study tested a combination of two drugs, alnuctamab and mezigdomide, in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find the best dose and check safety and early signs of effectiveness. The trial was stopped early and only enrolled 4 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0018

New York, New York, 10065, United States
Local Institution - 0020

Jerusalem, 9112001, Israel
Local Institution - 0021

Petah Tikva, Central District, 4910021, Israel
Local Institution - 0030

Ramat Gan, Central District, 5262100, Israel
Local Institution - 0033

Birmingham, Alabama, 35294, United States
Local Institution - 0035

New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA